Insulin-like growth factor-I: A treatment for type 2 diabetes revisited

Endocrinology

Volumn 147, Issue 6, 2006, Pages 2616-2618

  Murphy, Liam J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; SOMATOMEDIN C;

ANAMNESIS; CLINICAL PRACTICE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MICE; RECEPTOR, IGF TYPE 1;

EID: 33646811180     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0343     Document Type: Short Survey

References (19)

1. Lupulescu AP 1985 Effect of prolonged insulin treatment on carcinoma formation in mice.Cancer Res 45:3288-3295
2. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, Morroni M, Cinti S, White MF, Herrera PL, Accili D, Efstratiadis A 2002 Defective insulin secretion in pancreatic β cells lacking type 1 IGF receptor. J Clin Invest 110:1011-1019
3. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, Accili D 2002 Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and β-cell compensation to insulin resistance. J Biol Chem 277:36740-36747
4. Barett JR, Plewe G, Fagin KD, Sherwin RS 1989 Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 83:1717-1723
5. Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M, Perticone F 2005 Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28:120-125
6. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J 2000 The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85:1518-1524
7. Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G 2005 Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274
8. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC 1994 Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205-210
9. Laager R, Ninnis R, Keller U 1993 Comparison of the effects or recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest 92:1903-1909
10. Federici M, Giaccari A, Hribal ML, Giovannone B, Lauro D, Morviducci L, Pastore L, Tamburrano G, Lauro R, Sesti G 1999 Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes 48:2277-2285
11. Federici M, Porzio O, Lauro D, Borboni P, Giovannone B, Zucaro L, Hribal ML, Sesti G 1998 Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. J Clin Endocrinol Metab 83:2911-2915
12. Federici M, Lauro D, D'Adamo M, Giovannone B, Porzio O, Mellozzi M, Tamburrano G, Sbraccia P, Sesti G 1998 Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes 47:87-92
13. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695
14. Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, LeRoith D 2006 Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619-2630
15. Le Roith D, Kim H, Fernandez AM, Accili D 2002 Inactivation of muscle insulin and IGF-I receptors and insulin responsiveness. Curr Opin Clin Nutr Metab Care 5:371-375
16. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, Kahn CR 1998 A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2:559-569
17. Chang PY, Goodyear LJ, Benecke H, Markuns JS, Moller DE 1995 Impaired insulin signaling in skeletal muscles from transgenic mice expressing kinase-deficient insulin receptors. J Biol Chem 270:12593-12600
18. Cusi K, DeFronzo R 2000 Recombinant human insulin-like growth factor 1 treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85:3077-3084
19. Zhao H, Yakar S, Gavrilova O, Sun H, Zhang Y, Kim H, Setser J, Jou W, LeRoith D 2004 Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 53:2901-2909